Search for: "SANOFI-PHARMACEUTICALS, INC." Results 161 - 180 of 216
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
3 Mar 2010, 5:05 am
(IP Osgoode) Australia: University of Western Australia’s application to appeal FCAFC’s decision in University of Western Australia v Gray fails (IP Whiteboard) Colombia/EU/Peru: Tough IP health provisions in Europe’s Colombia/Peru trade deal (IP Watch) (IP tango) EU: Something more about Swiss type claims: G02/08 (SiNApSE) (SiNApSE) US: Pharmaceutical patent settlements – and what about patients? [read post]
18 Nov 2014, 11:16 am
  Indeed, the government has used this ban as the basis for a creeping administrative takeover of pharmaceutical and medical device public relations practices. [read post]
23 Sep 2021, 2:10 am by Rose Hughes
The US Courts of Appeal of the Federal Circuit (CAFC) found in Belcher Pharmaceuticals v Hospira, Inc that a formulation patent was unenforceable in view of inequitable conduct, in the form of contradictory submissions to the patent office and the regulatory agency (FDA) by the patentee. [read post]
3 Jan 2013, 4:00 am by Alan Macek
Justice Snider has written in Sanofi-Aventis Canada Inc v Novopharm Ltd, 2009 FC 1139: A review of recent jurisprudence on the issue of awards in intellectual property trials indicates that this scale recognizes the significance and complexity of the various issues in such a trial. [read post]
1 Jul 2009, 7:14 am
OHIM decision in Laboratorios Andrómaco, S.A. v OTC Pharma International B V (Class 46) India: Valgancyclovir hearings and the need for more transparency: Roche v Cipla (Spicy IP) Japan approves first follow-on biologic (Patent Docs) UK: Journal of Intellectual Property Law & Practice note on ‘Paediatric extensions: the requirement of a compliance statement’ on UK IPO decision in Merck and Co, Inc (The SPC Blog) US: Sen Nelson introduces s 1315 bill to… [read post]
18 Feb 2020, 4:00 am by Martin Kratz
Pfizer Canada ULC, 2020 FC 1, at para. 42. [3] See Sections 27(3)(b) and 28.3 of the Patent Act, RSC 1985, c P-4 [4] Burton Parsons Chemicals, Inc v Hewlett-Packard (Canada) Ltd, [1976] 1 SCR 555 at 563 [5] Apotex Inc v Sanofi-Synthelabo Canada Inc, 2008 SCC 61 at paragraph 37, [2008] 3 SCR 265; see also Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219 at paragraph 65; Mylan… [read post]
3 Aug 2011, 3:31 am by Marie Louise
Application fee increases by a whopping 19.4% (or almost $300K) (FDA Law Blog) US: Life sciences venture funding up 37% in second quarter (Patent Docs)   Products Arava (Leflunomide) – Australia: FCA ‘evergreens’ Arava: Sanofi-Aventis Australia v Apotex (Patentology) Cambia (Diclofenac) – US: Nautilus files patent infringement complaint against Edict Pharmaceuticals in response to Para IV certification filing (Patent Docs) Cenestin – US: CAFC… [read post]
23 Dec 2007, 8:00 pm
You can separately subscribe to the IP Thinktank Global week in Review at [feeds.feedburner.com]GlobalEvents in Bali heap further pressure on all IP owners: (IAM),Velcro defies generic claim in domain name battle: (OUT-LAW),ICANN forms group to hasten non-English domain names: (IP Justice)WTO members continue debate on geographical indications register: (Intellectual Property Watch),Creative Commons launches CCo and CC programs: (World IP Day),Green IP Strategy - risks… [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
26 Apr 2021, 7:42 am by Race to the Bottom
Companies whose initial vaccine efforts failed, such as Merck & Co. and Sanofi, have partnered with Johnson & Johnson and Pfizer Inc., respectively, to help ramp up vaccine supply. [read post]
25 Jan 2008, 1:00 am
: (Generic Pharmaceuticals & IP),Arava (Leflunomide) - Sanofi-Aventis loses bid to dismiss Louisiana Wholsesale Drug Co's antitrust claims accusing S-A of unlawfully blocking generic competition for Arava by filing a sham Citizen Petition with the USFDA: (IP Law360),Ciprofloxacin - CIPLA issued notice by National Pharmaceutical Pricing Authority for allegedly overpricing its antibiotic Ciprofloxacin (especially of note… [read post]
26 Sep 2022, 4:49 am by Dennis Crouch
Skinny Label Infringement in Teva Pharmaceuticals USA, Inc. v. [read post]
16 Feb 2014, 4:00 am by Administrator
” LEAVES TO APPEAL GRANTED Pharmaceuticals: Utility; Obviousness Is the patent valid here.Apotex Inc., et al. v. [read post]